Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events

Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events

Background: Serious adverse events (SAEs) and subject replacements occur frequently in phase 1 oncology clinical trials. Whether baseline quality-of-life (QOL) or social support can predict risk for SAEs or subject replacement among these patients is not known. Methods: Between 2011–2013, 92 patient...

Full description

Bibliographic Details
Main Authors: Sidra Anwar, Wei Tan, Chi-Chen Hong, Sonal Admane, Askia Dozier, Francine Siedlecki, Amy Whitworth, Ann Marie DiRaddo, Dawn DePaolo, Sandra M. Jacob, Wen Wee Ma, Austin Miller, Alex A. Adjei, Grace K. Dy
Format: Article
Language:English
Published: MDPI AG 2017-06-01
Series:Cancers
Subjects:
quality-of-life
QOL
EORTC QLQ-C30
FACT-G
MOSSSS
phase 1 cancer trial
oncology trials
immunotherapy
selection criteria
serious adverse events
Online Access:http://www.mdpi.com/2072-6694/9/7/73

Internet

http://www.mdpi.com/2072-6694/9/7/73

Similar Items